Swiss National Bank
KNSA icon

Swiss National Bank’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Swiss National Bank’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.44M Buy
71,500
+2,900
+4% +$128K ﹤0.01% 1561
2025
Q4 		$2.83M Buy
68,600
+2,900
+4% +$116K ﹤0.01% 1697
2025
Q3 		$2.55M Buy
65,700
+1,100
+2% +$35.7K ﹤0.01% 1729
2025
Q2 		$1.79M Sell
64,600
-7,300
-10% -$186K ﹤0.01% 1866
2025
Q1 		$1.6M Hold
71,900
– – ﹤0.01% 1892
2024
Q4 		$1.42M Sell
71,900
-6,700
-9% -$153K ﹤0.01% 2047
2024
Q3 		$1.96M Hold
78,600
– – ﹤0.01% 1870
2024
Q2 		$1.47M Buy
78,600
+23,000
+41% +$431K ﹤0.01% 1970
2024
Q1 		$1.1M Hold
55,600
– – ﹤0.01% 2172
2023
Q4 		$975K Sell
55,600
-5,100
-8% -$83.8K ﹤0.01% 2253
2023
Q3 		$1.05M Hold
60,700
– – ﹤0.01% 2218
2023
Q2 		$855K Sell
60,700
-6,400
-10% -$85.7K ﹤0.01% 2376
2023
Q1 		$722K Sell
67,100
-7,800
-10% -$103K ﹤0.01% 2407
2022
Q4 		$1.12M Buy
74,900
+2,600
+4% +$37.9K ﹤0.01% 2283
2022
Q3 		$928K Hold
72,300
– – ﹤0.01% 2377
2022
Q2 		$701K Buy
72,300
+12,200
+20% +$114K ﹤0.01% 2521
2022
Q1 		$597K Buy
60,100
+7,300
+14% +$77.3K ﹤0.01% 2559
2021
Q4 		$621K Hold
52,800
– – ﹤0.01% 2618
2021
Q3 		$601K Hold
52,800
– – ﹤0.01% 2560
2021
Q2 		$736K Sell
52,800
-1,400
-3% -$21.3K ﹤0.01% 2567
2021
Q1 		$1M Buy
54,200
+1,700
+3% +$34.8K ﹤0.01% 2343
2020
Q4 		$928K Hold
52,500
– – ﹤0.01% 2331
2020
Q3 		$804K Buy
52,500
+13,900
+36% +$261K ﹤0.01% 2207
2020
Q2 		$984K Buy
+38,600
New +$806K ﹤0.01% 2109
2019
Q4 		– Sell
-19,500
Closed -$166K – 2523
2019
Q3 		$166K Hold
19,500
– – ﹤0.01% 2506
2019
Q2 		$264K Buy
+19,500
New +$303K ﹤0.01% 2525

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Swiss National Bank's KNSA Position: Q1 2026 in Review

Swiss National Bank increased its Kiniksa Pharmaceuticals (KNSA) stake by 4.2% in Q1 2026, buying an estimated $128K and bringing the position to 71,500 shares worth $3.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

Swiss National Bank first reported a position in KNSA in Q2 2019 and has held it in 26 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Swiss National Bank held 71,500 shares of Kiniksa Pharmaceuticals worth $3.44M as of Q1 2026.
  • Swiss National Bank bought 2,900 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $128K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1561 holding.
  • Swiss National Bank first reported a position in Kiniksa Pharmaceuticals in Q2 2019 and has held it in 26 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.